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INTRODUCTION 
Identification of protein-ligand interaction networks on a proteome scale is crucial to address a wide range 
of biological problems such as correlating molecular functions to physiological processes and designing 
safe and efficient therapeutics. We have developed a novel computational strategy to identify ligand 
binding profiles of proteins across gene families and applied it to predicting protein functions, elucidating 
molecular mechanisms of drug adverse effects, and repositioning safe pharmaceuticals to treat different 
diseases. 
METHODS 
Our cross-gene-family approach proceeds as follows: 
1) The ligand binding site of the primary target is extracted or predicated from a 3D experimental structure 
or homology model of proteins and characterized by a geometric potential (1). 
2) Off-target proteins with similar ligand binding sites to the primary target are identified across human 
structural genomes based on a new algorithm for fast and accurate estimation of statistics significance 
of Sequence Order Independent Profile-Profile Alignment (SOIPPA) (2). 
3) The atomic details of interactions between the drugs and the putative off-targets from the step 2 are 
characterized using protein-ligand docking methods. The high ranking off-targets are further 
investigated using a normalized docking score. 
4) The identified panel of off-targets is subject to structural and functional cluster analysis and connected 
into a network including multiple metabolic, signal transduction, and gene regulation pathways. 
Combinatorial controls of biological process by the off-target are analyzed based the above established 
network.  
 
RESULTS 
 
The above strategy has been successfully applied to reveal the molecular mechanism for the adverse drug 
effects of selective estrogen receptor modulators (SERMs) from experimental structures (3). Moreover, we 
have discovered that the marketed pharmaceuticals Entacapone (ENT) and Tolcapone (TOL) used for 
treating Parkinson’s disease can potentially be repositioned to treat multi drug and extensively drug 
resistance tuberculosis (TB). The predication is based on the established evolutionary relationship between 
human SAM methyltransferases (including COMT) and M. tuberculosis enoyl-ACP reductase (InhA), both 
Rossmann fold proteins and the latter a major target of TB drugs (2). The inhibition by ENT and TOL of 
M. tuberculosis growth has been validated by microplate assay (Figure 1).  
 
Appling our approach on a proteome scale we extended the methodology to include homology models as 
target receptors and identified a panel of off-targets of cholesteryl ester transfer protein (CETP) inhibitors 
(Table 1). The CETP inhibitor is developed as a new preventive therapy for cardiovascular disease by 
raising HDL cholesterol. Clinical studies have indicated that one of the CETP inhibitors, Torcetrapib, has 
deadly off-target effect that result in the excess induction of hypertension (4). Consequently, it was 
withdrawn from the phase III clinical trial. In contrast with Torcetrapib, another CETP inhibitor JTT-705 
does not have unwanted side-effect that increases the blood pressure. The identified multiple off-targets of 
CETP inhibitors from our studies are involved in both positive and negative feedback controls of stress 
regulations and immune response through an interconnected metabolic, signal transduction, and gene 
regulation networks (Figure 2). Our predictions are strongly correlated to the clinical and in vitro 
observations, providing a molecular explanation on the difference in the side effect profile of the CETP 
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inhibitors. The finding further suggests that adverse drug reactions can be modulated by the fine-tuning of 
the off-target binding network. 
 
CONCLUSION 
 
In all of above cases, most of the identified off-targets belong to different protein superfamilies from the 
primary target. It indicates that complex protein-ligand interaction networks play key roles in physiological 
and pathological processes. Thus, a computational chemical genomics approach that systematically uses 
small molecules to probe biological systems will provide us with valuable clues as to the molecular basis of 
cellular functions and at the same time shift the conventional one-target-one-drug drug discovery process to 
a new multi-target-multi-drug paradigm.  
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Figure 1. Inhibition rate of M. tuberculosis by 
Entacapone (ENT) from microplate assay.  
The drugs ENT and TOL’s primary target catechol-O-
methyltransferase (COMT) belongs to a large 
superfamily of SAM methyltransferases. The drugs are 
used as adjuncts to treat Parkinson’s disease by 
increasing the bioavailability of the primary drug 
levodopa. ENT and TOL may inhibit the 
M.tuberculosis InhA protein directly – a different 
mechanism from the first- and second-line drugs that 
result in MDR and XDR strains. ENT and TOL have 
excellent safety profiles with few side effects.  
 
Figure 2. Correlations of the selected six classes of off-targets to the clinical observations through possible 
biological pathways. Green and blue lines indicate positive and negative regulation, respectively. 
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TABLES 
Table 1. Binding site volumes and normalized docking scores (NDS) of CETP inhibitors for CETP 
and six classes of putative off-targets. The predicated binding affinities are colored red (strong, 
NDS< -2.0), purple (relatively strong, 0.0>NDS> -2.0), and blue (weak, NDS>0.0), respectively.  
 
      Normalized Docking Score 
    
Protein 
 
PDB ID 
 
Binding Site 
Volume (Ǻ3) Torcetrapib anacetrapib JTT705 
CETP  2OBD  1084.2 -5.6024 -4.6705 -1.9644 
Retinoid X receptor 
(agonist) 
1YOW 1420.5 -5.5803 -4.1922 -0.9344 
PPARδ 
(agonist) 
1Y0S    
1313.2 
-3.8703 -3.8384 -1.5662 
PPARα  
(agonist) 
2P54  1059.4 -4.0828 6.6785 -3.0660 
PPARγ  
(agonist) 
1ZEO  726.5 -3.9838 6.0096 -2.0316 
LXRα 
(agonist) 
2ACL 1155.0 5.7793 6.3052 -0.6900 
LXRβ 
(agonist) 
1UPV 1553.5 5.0882 5.5450 -1.7543 
Vitamin D receptor  
(agonist) 
1IE8  879.7 5.7622 6.1759 -1.1761 
Glucocorticoid receptor 
(agonist) 
1P93 819.0 5.5504 6.1432 -2.0131 
Glucocorticoid receptor 
(antagonist) 
1NHZ 990.5 -2.1235 -3.2125 -1.1673 
Glycolipid  
transfer protein  
1TFJ  987.4 -0.9839 -2.1587 -1.3249 
Phosphatidylcholine 
transfer protein  
1LN1  1860.1 -7.3050 -9.1032 -1.0794 
Phosphatidylinositol 
transfer protein  
2A1L  2271.7 -4.0881 -6.0708 -1.7366 
GM-2 activator  
 
2AG9  955.0 -4.0254 -3.8265 -3.6934 
Fatty acid binding 
protein 
2NNQ 743.3 3.3521 6.8334 -2.3356 
T-Cell CD1B receptor  
 
1GZP  1056.4 -2.0899 -6.1531 -1.3424 
EF hand-like 
 
1DTL 1992.0 -3.7771 -3.6403 -2.9955 
Cytochrome complex 
 
1PP9 2963.0 -3.8702 -7.0825 -2.2745 
Human cytoglobin 
 
1V5H 1022.2 -3.4827 -1.8246 -2.3848 
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